It has been proposed that some polymorphisms in the CTLA-4 gene could be considered to be biomarkers of cancer susceptibility [34]; however, it has also been proposed that some genetic variants in this gene may serve as potential biomarkers predictive of favorable outcomes in melanoma patients treated with ipilimumab [35]. Here, CTLA4 is linked to melanoma.